title: Ischemia-modified albumin, a predictive marker of major adverse cardiovascular events in continuous ambulatory peritoneal dialysis patients.
abstract: OBJECTIVE
  The aim of this study was to evaluate the efficiency of ischemia-modified albumin (IMA) for predicting major adverse cardiovascular events (MACE) in continuous ambulatory peritoneal dialysis (CAPD) patients.
  
  
  METHODS
  A prospective observational study was conducted with 120 CAPD patients and 37 healthy volunteers. Demographic and clinical data were collected. The primary end point is the occurrence of MACE.
  
  
  RESULTS
  A total of 157 participants with a mean age of 43.64 years finally completed this study. The CAPD patients had a significantly high rate of MACE (P=0.001) and high levels of IMA than healthy controls (P<0.001). Compared with CAPD patients with normal levels of IMA, the CAPD patients with high levels of IMA (>85 kU/L) had lower non-MACE survival rate (P<0.001), which indicated that the high IMA CAPD patients may suffer a high rate of MACE. In addition, the high IMA CAPD patients also had a low level of serum albumin (P<0.001) and hemoglobin (P=0.018). The correlation analysis showed that the serum albumin level was the most effective factor influencing IMA (B=-0.967, P<0.001).
  
  
  CONCLUSIONS
  CAPD patients with high levels of IMA had a high incidence rate of MACE. IMA was a good predictive marker of MACE and might be important in cardiovascular risk stratification of CAPD patients.
authors.affiliation: Department of Nephrology, Donghua Hospital of Sun Yat-sen University, Dongguan 523000, China.
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Su
authors.forename: Kun
authors.initials: K
authors.lastname: Zhang
authors.forename: Faliang
authors.initials: F
authors.lastname: Guo
authors.forename: Bing
authors.initials: B
authors.lastname: Yuan
authors.forename: Cun
authors.initials: C
authors.lastname: Wang
authors.forename: Long
authors.initials: L
authors.lastname: Xiao
authors.forename: Jingfeng
authors.initials: J
authors.lastname: Wang
authors.forename: Hui
authors.initials: H
authors.lastname: Huang
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000097:blood* / Q000175:diagnosis / Q000209:etiology / Q000401:mortality; D016022:Case-Control Studies; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000175:diagnosis / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011446:Prospective Studies; D012307:Risk Factors; D012709:Serum Albumin; D000075462:Serum Albumin, Human; D015996:Survival Rate
chemical_list: D015415:Biomarkers; D006454:Hemoglobins; D012709:Serum Albumin; C561522:ischemia-modified albumin; D002097:C-Reactive Protein; D000075462:Serum Albumin, Human
keywords: ACS; CAPD; Continuous ambulatory peritoneal dialysis; DBP; ESRD; IMA; Ischemia-modified albumin; LDL-c; MACE; Major adverse cardiovascular events; Predictive value; SBP; TC; WBC; acute coronary syndromes; continuous ambulatory peritoneal dialysis; diastolic blood pressure; end-stage renal disease; high sensitivity CRP; hs-CRP; ischemia-modified albumin; low density lipoprotein cholesterol; major adverse cardiovascular events; no occurrence of MACE; non-MACE; systolic blood pressure; total cholesterol; white blood cell